Insights Into Breast Cancer 2020 Southeast

Community physician perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents

Southeast July 8, 2020

Faculty Chair

Adam Brufsky, MD, PhD

UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of metastatic breast cancer was held via a virtual platform on July 8, 2020
  • Disease state and data presentations were developed in conjunction with Adam Brufsky, MD, PhD, a medical expert from the University of Pittsburgh
  • Insights on the following therapies were obtained:
    • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
    • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, tucatinib, neratinib, AIs, mTOR inhibitors, chemotherapies
    • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies
  • Data collection was accomplished through use of audience response system questioning and moderated discussion

GEOGRAPHIC REPRESENTATION

  • The group of advisors comprised community oncologists from the southeast region of the United States
  • Attendees of the roundtable represented community oncologists from Florida, Georgia, South Carolina, and Virginia

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.